Thor Medical ASA Logo

Thor Medical ASA

Sustainably produces alpha-emitters from thorium for cancer therapies, without nuclear reactors.

NANOV | OL

Overview

Corporate Details

ISIN(s):
NO0010597883 (+1 more)
LEI:
5967007LIEEXZXG6DK30
Country:
Norway
Address:
Drammensveien 167, 0277 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Thor Medical ASA is an emerging producer and supplier of radionuclides for medical use, specializing in alpha-particle emitters for targeted alpha therapies in oncology. The company has developed a proprietary technology for manufacturing these isotopes by separating naturally occurring radioactive decay products from thorium. This novel process eliminates the need for nuclear reactors or cyclotrons, providing a more efficient, cost-competitive, and environmentally sustainable alternative to traditional production methods.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 56.4 KB
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 6.2 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 50.3 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 2.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228 - …
English 64.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228
English 7.7 KB
2025-08-01 08:58
Declaration of Voting Results & Voting Rights Announcements
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 46.1 KB
2025-08-01 08:58
Share Issue/Capital Change
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 2.0 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering - Attachment: Downlo…
Norwegian 59.1 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering
Norwegian 10.1 KB
2025-07-03 07:00
Share Issue/Capital Change
Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16…
Norwegian 62.0 KB
2025-07-03 07:00
Share Issue/Capital Change
Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16…
English 10.1 KB
2025-06-26 14:33
Director's Dealing
Thor Medical ASA: Primary insider notification and disclosure of large sharehol…
English 120.0 KB
2025-06-26 14:33
Major Shareholding Notification
Thor Medical ASA: Primary insider notification and disclosure of large sharehol…
English 51.7 KB
2025-06-26 14:33
Major Shareholding Notification
Thor Medical ASA: Primary insider notification and disclosure of large sharehol…
English 3.9 KB

Automate Your Workflow. Get a real-time feed of all Thor Medical ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Thor Medical ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Thor Medical ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.